.jpg)
Amid uncertainty in the US, Boehringer Ingelheim projects 'slight' revenue increase for '25
Boehringer Ingelheim picked a challenging day to reveal its 2024 financial results and guidance for this year. With President Donald Trump announcing his plan on tariffs on Wednesday and uncertainty surrounding if and how they will affect the export of pharmaceutical products to the U.S., the German company is treading lightly with its projection of a “slight year-on-year increase” in revenue.
Boehringer Ingelheim picked a challenging day to reveal its 2024 financial results and guidance for this year. With President Donald Trump announcing his plan on tariffs on Wednesday and uncertainty surrounding if and how they will affect the export of pharmaceutical products to the U.S., the German company is treading lightly with its projection of a “slight year-on-year increase” in revenue.
